Jade Biosciences (JBIO) Total Non-Current Liabilities (2021 - 2025)

Jade Biosciences has reported Total Non-Current Liabilities for 5 years, with the latest figure at $2.4 million in Q1 2025.

• For the quarter ending Q1 2025, Total Non-Current Liabilities fell 84.75% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2025 stood at $2.4 million (down 84.75% YoY), and the FY2024 full-year result was $12.0 million, down 32.95% from the prior year.
• Total Non-Current Liabilities for Q1 2025 stood at $2.4 million, down from $12.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $17.9 million in Q4 2023, with the low at $2.4 million in Q1 2025.
• Historically, Total Non-Current Liabilities has averaged $10.4 million across 5 years, with a median of $10.8 million in 2023.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 197.96% — and 2025, when it plunged 84.75%.
• Jade Biosciences' Total Non-Current Liabilities stood at $2.9 million in 2021, then surged by 189.46% to $8.5 million in 2022, then jumped by 110.82% to $17.9 million in 2023, then plunged by 32.95% to $12.0 million in 2024, then tumbled by 79.85% to $2.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $2.4 million (Q1 2025), $12.0 million (Q4 2024), and $10.4 million (Q3 2024), per Business Quant data.